This study is currently not recruiting participants.

A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; NSC: 783609) in Children With Relapsed or Refractory Wilms Tumor Rhabdomyosarcoma Neuroblastoma Pleuropulmonary Blastoma Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma

  • STATUS
    Not Recruiting
Send
Updated on 19 February 2024

Summary

This phase II trial studies how well lorvotuzumab mertansine works in treating younger patients with Wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor (MPNST), or synovial sarcoma that has returned or that does not respond to treatment.

Description

The purpose of this study is to assess the efficacy of IMGN901 (lorvotuzumab mertansine) in Wilms tumor, rhabdomyosarcoma, neuroblastoma and other cluster of differentiation (CD)56-expressing tumors such as pleuropulmonary blastoma, malignant peripheral nerve sheath tumor (MPNST) and synovial sarcoma; to determine the tolerability of the adult recommended phase 2 dose (RP2D) of IMGN901 administered as an intravenous infusion, administered on days 1 and 8 of a 21-day cycle, to children with refractory Wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, MPNST, or synovial sarcoma; and to define and describe the toxicities of IMGN901 administered on this schedule.

Details
Condition Wilms Tumor
Age 1years - 30years
Clinical Study IdentifierTX5834
Last Modified on19 February 2024

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.